Alzheimer's Research Faces Crisis as Major Drug Trials Continue to Fail
Two major drug trials testing the effectiveness of gantenerumab, a drug designed to clear amyloid beta proteins in the brain, have failed to show significant improvements in cognitive function for people with early Alzheimer's disease. While the drug successfully reduced amyloid plaque burden, it did not translate into slower clinical decline. These results come at a critical juncture for the amyloid hypothesis, which has been the dominant theory for Alzheimer's disease. Controversial drug approvals based on thin evidence and mixed results from other anti-amyloid drugs have raised doubts about the effectiveness of targeting amyloid beta proteins. The search for effective treatments for Alzheimer's disease continues.
